The Centers for Disease Control and Prevention has recommended Pfizer-BioNTech COVID-19 booster shots for adolescents ages 12 through 17, extending the national booster campaign to millions of teenagers as the Omicron variant drives infections to unprecedented levels and schools reopen after the holidays.

CDC Director Rochelle Walensky endorsed the agency advisory committee's recommendation Wednesday, saying adolescents should receive a booster five months after completing their initial Pfizer-BioNTech series. The CDC announcement said the recommendation applies to 12- through 17-year-olds and follows review of safety information encompassing more than 25 million vaccine doses administered to adolescents.

FDA action opened the door earlier in the week

The recommendation follows a Food and Drug Administration decision Monday expanding the Pfizer-BioNTech emergency use authorization to include booster doses for people ages 12 through 15. The FDA notice also shortened the minimum interval between the Pfizer primary series and a booster from six months to five and authorized an additional primary-series dose for certain immunocompromised children ages 5 through 11.

Pfizer and BioNTech said the adolescent booster uses the same 30-microgram dose authorized for older recipients. Their January 3 statement called the decision the first U.S. authorization of a COVID-19 booster for adolescents ages 12 through 15 and argued that broad booster use is increasingly important as Omicron reduces protection against infection.

The regulatory action came as schools, airlines, health systems and employers were confronting widespread absences associated with the fast-moving variant. A Washington Post report said the FDA decision was part of a broader effort to strengthen protection while Omicron disrupted schools and businesses across the country.

Advisers weigh benefits against myocarditis risk

The CDC's Advisory Committee on Immunization Practices met Wednesday to review safety, effectiveness and benefit-risk evidence before voting on the adolescent recommendation. The agency's meeting archive shows presentations on vaccine safety, the evidence-to-recommendations framework and booster dosing in adolescents ages 12 through 15.

The central safety issue remains myocarditis and pericarditis, rare inflammatory heart conditions observed most often in adolescent and young adult males after mRNA vaccination, particularly after a second dose. Federal advisers weighed that known risk against the rapidly rising number of infections, the protection vaccination provides against severe disease and the possibility that Omicron could expose large numbers of adolescents to the virus in a short period.

Walensky said the available evidence supported moving forward. The CDC stated that vaccination and boosting can broaden and strengthen protection against Omicron and other variants, and that the safety data reviewed by advisers continued to support use of the vaccine in adolescents.

The five-month interval broadens eligibility immediately

The policy change is not limited to teenagers. On Tuesday, CDC shortened the recommended Pfizer booster interval from six months to five months for eligible recipients. Its January 4 guidance also recommended an additional primary dose for moderately or severely immunocompromised children ages 5 through 11, 28 days after their second Pfizer dose.

The shorter interval means millions of people who completed their Pfizer primary series in late summer can become eligible for boosters sooner than previously expected. The change is intended to respond to evidence that protection against infection declines over time and that Omicron is substantially better than earlier variants at infecting people who have received only a primary series.

A contemporaneous Reuters account noted that the FDA moved the booster interval to five months as schools reopened and health officials warned that Omicron's transmissibility could strain health systems.

Boosters become part of the school-age response

For families, the recommendation creates a new distinction between being vaccinated and being up to date. Adolescents who completed two Pfizer doses may now be advised to receive a third once five months have passed. The American Academy of Pediatrics, in a January 3 update, highlighted the FDA authorization while also noting the parallel changes for immunocompromised younger children.

The decision comes during a difficult period for schools. Omicron is producing large numbers of infections even among vaccinated people, while isolation rules, staff shortages and student absences are forcing districts to reconsider how they maintain in-person instruction. The booster recommendation does not eliminate breakthrough infections, but federal officials are emphasizing its role in restoring immune protection and reducing the risk of severe outcomes.

Only the Pfizer-BioNTech vaccine is currently authorized and recommended as a booster for adolescents under 18. Moderna and Johnson & Johnson vaccines remain options for many adults, but the adolescent campaign therefore depends on a single product and a five-month schedule tied to the Pfizer primary series.

The latest policy shift reflects how quickly the vaccination strategy is evolving in response to Omicron. In less than a week, federal regulators and advisers have expanded adolescent booster eligibility, shortened the Pfizer booster interval and added a third primary dose for some immunocompromised children. The next test is operational: converting those recommendations into appointments while families and schools navigate a wave that is spreading faster than any previous phase of the pandemic.